soul trial oral semaglutide cardiovascular outcomes soul trial results 2025 nejm Heart disease is the #1 cause of death in type 2 diabetes — and for the first soul trial oral semaglutide cardiovascular

Weeks 5 through 8: tirzepatide 5 mg At week 5, your provider will typically increase your dose to 5 mg

The pairing logic above is mechanistic and based on CagriSema results

Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite clinical trials version

In-Use Storage: Once opened, you can keep the vial/pen at room temperature (below 30C) or in the refrigerator for up to 30 days

Common Gastrointestinal Side Effects Besides nausea, other digestive complaints frequently reported in clinical trials include: Vomiting: Often accompanies severe nausea, more common at higher doses